Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU, US rosiglitazone decisions spark action in other countries

This article was originally published in SRA

Executive Summary

A number of countries have issued regulatory notices regarding rosiglitazone-containing products following last week's decision by the European Medicines Agency to suspend marketing authorisation for all such products and by the US Food and Drug Administration to impose severe new restrictions on the use of GlaxoSmithKline's rosiglitazone-containing drug, Avandia, because of potential cardiovascular risks associated with the drug1.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS115595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel